Infection with the dimorphic fungus Sporothrix schenckii usually leads to lymphocutaneous involvement; less often, infection is characterized by visceral or osteoarticular manifestations. Lymphocutaneous sporotrichosis has been successfully treated with saturated solution of potassium iodide (SSKI), but SSKI is usually ineffective for treatment of visceral and osteoarticular sporotrichosis [1] . In addition to its limited therapeutic value, SSKI therapy is often associated with significant side effects. Results oftreatment of sporotrichosis with ketoconazole have been disappointing [2] [3] [4] . Itraconazole has proved to be effective for treatment of both lymphocutaneous and osteoarticular sporotrichosis [5] [6] [7] [8] . However, no antifungal agent, including amphotericin B, has proved very effective for treatment of pulmonary sporotrichosis [8, 9] .
Preliminary studies noted that lymphocutaneous sporotrichosis responded to treatment with fluconazole at daily doses of 200-400 mg [10, 11] . In addition, fluconazole has been shown to be efficacious for treatment of other endemic mycoses, such as blastomycosis [12] . This study was undertaken by the National Institute of Allergy and Infectious Diseases Mycoses Study Group to assess the safety and efficacy of different doses of fluconazole for treating lymphocutaneous, visceral, and osteoarticular sporotrichosis.
Patients and Methods
Entry criteria. Patients had to have presumptive evidence of sporotrichosis to enter the study and had to have cultureproven sporotrichosis to remain in the study. Patients with acute life-threatening disease or eNS sporotrichosis were excluded from the study. In addition, patients infected with HIV, children younger than 12 years of age, pregnant women, nursing mothers, patients whose results of liver function tests were greater than five times the upper limit of normal, and patients receiving treatment with drugs known to interact with fluconazole were excluded from the study. Those patients who had received > 3 days of systemic antifungal therapy for a current episode of sporotrichosis were excluded from the study, and patients who had relapsing disease following prior antifungal therapy had to have a positive culture for S. schenckii before entry into the study.
Treatment regimen. In this phase 2 study, patients were initially randomized to be treated with an oral fluconazole regimen of either 200 mg or 400 mg daily. A reduction in the dose of fluconazole was allowed for patients with reduced renal function. After the first 13 patients were randomized and the response appeared to be less than expected, the dose of fluconazole was changed to 400 mg. Preliminary analysis of the first 25 patients treated led to a further increase in the daily dose of fluconazole to 800 mg for all patients continuing therapy mas but no yeasts. Of the 30 evaluable patients, 25 were men, and 5 were women; 22 were White, 4 were Hispanic, 3 were African American, and 1 was Native American. Fourteen patients had lymphocutaneous sporotrichosis; the mean age of these patients was 42.6 :t 5.1 years. Sixteen patients had visceral or osteoarticular involvement; the mean age of these patients was 51.8 :t 2.7 years (table 1) .
Fluconazole regimens. Ofthe 30 patients with documented sporotrichosis, 4, 19, and 2 patients received 200 mg, 400 mg, and 800 mg of fluconazole daily, respectively, during the entire treatment course. An additional two patients randomized to be treated with 400 mg daily received only 100 mg daily because of renal insufficiency. The daily dose of fluconazole was increased to 800 mg per the amended protocol for two other patients. One patient had renal failure and initially received 200 mg of fluconazole daily; the dose was increased to 400 mg after the protocol was modified.
Prior antifungal therapy. Eleven patients had received prior antifungal therapy for sporotrichosis and had relapsed before entry into the study. Four patients (three with lymphocutaneous lesions and one with osteoarticular sporotrichosis) had received SSKI therapy for 1 month to 4.5 years. Two patients with osteoarticular sporotrichosis had received amphotericin B treatment; one was treated for 5 months, and one was treated for an undetermined length of time. One patient was given ketoconazole therapy for 3 months for lymphocutaneous sporotrichosis, and another was given itraconazole therapy for 6 months for osteoarticular sporotrichosis. Three other patients had been given sequential therapy; one was treated with amphotericin B followed by ketoconazole for osteoarticular sporotrichosis for >2 years, one was treated with amphotericin B followed by itraconazole for osteoarticular sporotrichosis for 8 months, and one was treated with SSKI followed by itraconazole for lymphocutaneous sporotrichosis for a total of 15 months.
Underlying illnesses. Underlying illnesses were common in patients with osteoarticular or visceral sporotrichosis but not in those with lymphocutaneous sporotrichosis (P = .06) (table 2). Of the 16 patients with visceral or osteoarticular sporotrichosis, 75% had one or more underlying illnesses, with alcoholand for subsequent patients entering the trial. Patients were to receive treatment for at least 3 months, at which time fluconazole therapy could be discontinued. The investigators had the option to continue administering the drug for as long as 24 months depending on the clinical response of the patient. All patients were to be followed up for a minimum of 1 year after therapy was stopped.
Evaluation of toxicity and efficacy. At the time of entry into the study, every 2 weeks for the first 2 months, and monthly thereafter while fluconazole therapy was administered, the patient was examined, symptoms and signs were recorded, and the following laboratory data were obtained: complete blood cell count with differential cell count, erythrocyte sedimentation rate, results of liver function tests, blood urea nitrogen level, serum creatinine level, prothrombin time, partial thromboplastin time, and results of urinalysis. In addition, fungal cultures were performed if lesions were present during any of these visits, and roentgenography and imaging procedures were performed as appropriate. Invasive procedures, such as skin biopsy, synovial fluid aspiration, or deep-tissue biopsy, were not repeated unless indicated clinically. Roentgenograms and scans were obtained every 3 months until they revealed no abnormalities.
Clinical evaluation. Treatment that was administered for a minimum of 1 month was classified as either a success or a failure on the basis of response of symptoms and signs, laboratory values, roentgenograms and scans, and follow-up culture results. Success was defined as follows: cured,~75% reduction of symptoms and signs of infection,~75% reduction of the size of lesions on roentgenograms, and negative cultures at the end of therapy and during follow-up; and improved,~25% but <75% change in signs and symptoms of infection and roentgenographic findings and negative cultures at the end of therapy and during follow-up.
Failure was defined by the following different outcomes: progressive disease, a lesion that was present at the time of therapy increased or a new lesion developed; persistence of disease, there was no decrease in signs and symptoms, radiographs did not reveal improvement, and cultures remained positive; relapsing disease, infection recurred after successful therapy with fluconazole; drug toxicity, an adverse effect necessitated stopping therapy; and death due to sporotrichosis.
Statistical methods. This study was primarily descriptive. Fisher's exact test was utilized to compare the prevalence of underlying diseases with the type of sporotrichosis and also to compare the response rates for lymphocutaneous and osteoarticular or visceral sporotrichosis.
Results
Patient demographics. Thirty-two patients were enrolled in the study. Two patients with lymphocutaneous lesions were excluded from the analysis of efficacy because they had negative cultures and histopathologic examination showed granulo- NOTE. The differences in underlying illnesses between the two forms of sporotrichosis trended toward significance (P = .06, Fisher's exact test).
* Several patients had more than one underlying illness.
ism noted most commonly. All patients with pulmonary sporotrichosis had chronic obstructive pulmonary disease. In contrast, most patients with lymphocutaneous involvement were healthy, and only 36% had any underlying disease.
Clinical response to lymphocutaneous disease. The mean time of treatment for the 14 evaluable patients with lymphocutaneous sporotrichosis was 8.8 ± 1.4 months. Fluconazole therapy was successful for 10 (71%) of the 14 patients (table 3) . Of these 10 patients, 1 received 200 mg daily, 6 received 400 mg daily, 2 were treated with 400 mg initially and then with 800 mg daily, and 1 received 800 mg daily. Only two of the 10 patients who responded to fluconazole treatment had received prior therapy for sporotrichosis; both had received short courses of SSKI treatment.
Fluconazole therapy failed for four patients with lymphocutaneous sporotrichosis. Two of these patients responded initially; however, one had a clinical relapse during the 23rd month of treatment, and the other relapsed 6 months after a 10-month course had been completed. One patient with persistent lesions for whom cultures were positive for S. schenckii was an alcoholic and was noncompliant with therapy. The remaining patient's lesions progressed over 3 months; he was then treated with SSKI and responded to treatment. Of the four patients for whom treatment failed, one received 200 mg of fluconazole daily, and three received 400 mg of fluconazole daily; thus, therapy did not fail for the three patients who received 800 mg of fluconazole daily. Prior therapy with SSKl, ketoconazo1e, or SSKI followed by itraconazole also failed for three of the four patients for whom fluconazole treatment failed.
All but three patients with lymphocutaneous sporotrichosis were followed up for at least 1 year after therapy and did not experience any relapses. Of the three patients lost to follow- up, the condition of one clinically improved by month 2; however, this patient did not return for follow-up, and this patient's response is labeled as improved only. One patient was cured after 6 months of therapy but did not return for follow-up after treatment was stopped. One patient refused to return for regular follow-up and was withdrawn from the study. He was followed up indirectly through his personal physician and continued to receive treatment with 400 mg of fluconazole daily; his response is listed as a probable cure. Clinical response to osteoarticular or visceral disease. The mean length of therapy for the 16 patients with osteoarticular or visceral sporotrichosis was 8.8 ± 1.5 months. The outcome for only five (31%) of the 16 patients was favorable (table 3) . Only three of these five patients had eradication of sporotrichosis. Two of these three patients had osteoarticular disease (one received 400 mg of fluconazole daily and one received 800 mg of fluconazole daily), and the third patient had bursitis and pericarditis that were cured with 400 mg of fluconazole daily. The conditions of the two patients with cavitary pulmonary sporotrichosis who received therapy with 200 mg and 400 mg of fluconazole daily, respectively, improved clinically, but their chest roentgenograms did not show resolution after 11 and 15 months of therapy. Both patients were lost to long-term followup, and their responses are listed as improved only. None of the five patients with favorable responses had received prior therapy for sporotrichosis.
Fluconazole therapy failed for 11 patients with visceral or osteoarticular sporotrichosis. Four patients had progressive infection while receiving treatment with 200 mg (one patient) or 400 mg (three patients) of fluconazole daily. Five patients had persistent disease while receiving therapy with 400 mg of fluconazole daily. Two other patients did well while receiving treatment with 400 mg of fluconazole daily, but both relapsed Underlying illness within 3 months of stopping therapy. Prior therapy for sporotrichosis for 6 of these 11 patients had failed: 2 had received amphotericin B alone; 2, amphotericin B followed by itraconazole or ketoconazole; 1, SSKI; and 1, itraconazole.
Overall, of the 4 patients with pulmonary sporotrichosis, 2 had improved conditions, 1 had progressive infection, and 1 had persistent infection. Thus, there were no patients with pulmonary sporotrichosis for whom a cure was documented. Of the 13 patients who had osteoarticular involvement, 3 were cured, 2 responded initially but relapsed within 3 months (infection in 1 patient relapsed in a different joint), 4 had persistent infection, and 3 had progressive infection. One patient's tenosynovitis was cured, but his pulmonary lesions progressed while he received therapy.
Toxicity. Side effects were evaluated in all 32 patients who received fluconazole therapy, including the two patients without culture-proven sporotrichosis; these effects were uncommon. The most common side effect was alopecia, which occurred in five patients (16%). Hair loss began after 3-6 months of therapy, was reversible when treatment was stopped, and occurred only in those patients taking 400 mg (four patients) or 800 mg (one patient) daily. In addition, 3 patients had nausea, 2 had fatigue, and 1 each had anorexia, abdominal cramps, dizziness, dry skin, and painful dry cracked lips. One patient had impotence and gynecomastia, but it was thought that these symptoms were not related to the use of fluconazole. None of these side effects required that therapy be stopped or that the dose be decreased. One additional patient had a prolonged prothrombin time, and the dose of warfarin had to be decreased while he was receiving fluconazole therapy. One patient died during the study. He had received fluconazole treatment for only 11 days when he and his family decided to stop all but palliative care for his underlying illness, and he died 2 weeks later.
Discussion
This trial was undertaken in an attempt to find more efficacious therapy than that currently available for treatment of localized and disseminated sporotrichosis. Overall, these results are not encouraging for using fluconazole for treatment of sporotrichosis. Patients with lymphocutaneous disease had a moderately good response (success rate, 71%), but this response was less favorable than that noted with itraconazole therapy [5, 7, 8] . Among patients treated with itraconazole, SharkeyMathis et al. [8] found a response rate of 89% and Restrepo et al. [5] found a response rate of 100%. It is important to note, however, that three of the four patients in our study for whom treatment failed had relapsed after prior therapy for sporotrichosis: one had received ketoconazole for 3 months, one had received SSKI for 5 months and itraconazole for 10 months, and one had been intermittently treated with SSKI for a total of 4.5 years. Perhaps these patients had more extensive disease than most patients with lymphocutaneous sporotrichosis, and thus therapy with any antifungal agent would have been difficult. Our results of fluconazole treatment are similar to those reported by Diaz et al. [10] who found that only 13 (68%) of 19 patients treated with 100-400 mg of fluconazole had resolution of infection.
Fluconazole was not efficacious for treatment of osteoarticular sporotrichosis. Only three of 13 patients had complete eradication of infection. These results are less favorable than those noted with treatment with itraconazo1e [6, 8] or amphotericin B [13] . Winn et al. [6] reported that osteoarticular sporotrichosis in four of five patients was cured when itraconazole therapy was given for 8 months to >2 years [6] . Sharkey-Mathis et al. [8] found that 12 (86%) of 14 patients with osteoarticular sporotrichosis responded to itraconazole therapy, but four of the 12 patients later relapsed; therefore, overall only 57% of patients were cured with itraconazole therapy. Three of our patients for whom treatment failed were subsequently treated with itraconazole, and S. schenckii infection was eradicated in these cases. Similar to those patients described by Sharkey-Mathis et al. [8] , six of the 13 patients with osteoarticular sporotrichosis had relapsed after prior therapy with amphotericin B, itraconazole, ketoconazole, or SSKI. Thus, these patients had difficult-to-treat disease. However, comparing these results with those found with itraconazole therapy, fluconazole still appears to be less effective for treatment of this form of sporotrichosis [6, 8] .
All four patients with pulmonary sporotrichosis had underlying chronic obstructive pulmonary disease, and two of the four were also alcoholics. Although the conditions of two patients improved clinically, their chest roentgenographic abnormalities did not resolve, and cure could not be documented. These dismal results are similar to those noted with treatment with itraconazole, amphotericin B, ketoconazole, and SSKI [8, 9] .
The only significant toxic effect of fluconazole therapy was hair loss, which occurred in 16% of the patients. Pappas et al. [14] described reversible alopecia in 33 patients receiving fluconazole therapy, including the five patients from this study. Alopecia appeared to be dose related, was most commonly associated with the 400-mg or 800-mg daily dose, and occurred after several months of therapy.
A direct comparison of fluconazole with itraconazole cannot be made since the drugs were not studied in a comparative fashion. However, results of our study and other studies of histoplasmosis, blastomycosis, and sporotrichosis show that response rates with fluconazole therapy are lower than those noted with itraconazole therapy for these indolent fungal diseases [6, 8, 15] . It is tempting to speculate whether the response rates would have been better if more patients had been treated with 800 mg of fluconazole daily. There were too few patients treated at the higher dosage of fluconazole to address this speculation.
For the occasional patient with sporotrichosis who cannot absorb itraconazole or cannot tolerate the drug because of side effects or drug interactions, fluconazole might be an alternative cm 1996;22 (January) treatment. While fluconazole therapy should be reserved primarily for patients with lymphocutaneous sporotrichosis, an occasional patient with osteoarticular or visceral sporotrichosis may benefit from fluconazole as a second-line therapy. A minimum daily dose of 400 mg should be used for treatment of lyrnphocutaneous sporotrichosis, and 800 mg daily is probably appropriate for treatment of osteoarticular or visceral sporotrichosis.
